Suplementação com cholecalciferol em pacientes com doença renal crônica e hipovitaminose D

Detalhes bibliográficos
Ano de defesa: 2011
Autor(a) principal: Garcia-Lopes, Miriam Ghedini [UNIFESP]
Orientador(a): Não Informado pela instituição
Banca de defesa: Não Informado pela instituição
Tipo de documento: Tese
Tipo de acesso: Acesso aberto
Idioma: por
Instituição de defesa: Universidade Federal de São Paulo (UNIFESP)
Programa de Pós-Graduação: Não Informado pela instituição
Departamento: Não Informado pela instituição
País: Não Informado pela instituição
Palavras-chave em Português:
Link de acesso: http://repositorio.unifesp.br/handle/11600/10101
Resumo: Background: The effective protocol for treatment of hypovitaminosis D in non-dialysis dependent chronic kidney disease (NDD-CKD) patients has not yet been defined. In the present study we aimed to investigate the impact of cholecalciferol supplementation on serum markers of bone and mineral metabolism using the K/DOQI recommendation for NDD-CKD patients with vitamin D insufficiency. Methods: This was a prospective, randomized, single-blinded interventional study with 6 month of follow-up. This study included 75 patients, randomly assigned for the cholecalciferol group (n=38; 50,000 IU per month for 6 months) or for the placebo group (n=37). Results: After cholecalciferol supplementation, 25(OH)D levels increased significantly at 3 and 6 months in the intervention group and was maintained in the placebo group. No change was found in serum parathyroid hormone as well as in the other serum markers of mineral metabolism studied during the follow-up in both groups. In the end of the study, 46% of the treated patients did not achieve 25(OH)D levels higher than 30 ng/mL. This group of patients had a greater body fat index when compared with those who achieved this level. In the placebo group 40.5% increased 25(OH)D levels higher than 30 ng/mL after 6 months. The season (summer/autumn) when blood was collected for 25(OH)D determination was the only parameter that differed from the group of patients who maintained 25(OH)D levels below 30 ng/mL. Conclusion: Our results indicate that the protocol for treatment of vitamin D insufficiency proposed by the K/DOQI guideline seems not to be adequate for completely restore the vitamin D status of NDD-CKD patients. The lack of adequate response to cholecalciferol supplementation together with the unpredicted restoration of vitamin D status in the placebo group may account, at least in part, for the negative results of the present study.